A number of research firms have changed their ratings and price targets for Azenta (NASDAQ: AZTA):
- 11/14/2026 – Azenta was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/12/2026 – Azenta is now covered by Zacks Research. They set a “hold” rating on the stock.
- 11/11/2026 – Azenta had its price target raised by Needham & Company LLC from $37.00 to $57.00. They now have a “buy” rating on the stock.
- 11/11/2026 – Azenta had its price target raised by Jefferies Financial Group from $44.00 to $52.00. They now have a “buy” rating on the stock.
- 10/18/2026 – Azenta was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/10/2026 – Azenta was upgraded by Wall Street Zen from “hold” to “buy”.
Azenta Stock Up 3.5%
Shares of NASDAQ:AZTA traded up $1.62 during mid-day trading on Monday, reaching $47.27. 289,445 shares of the stock were exchanged, compared to its average volume of 943,669. The stock’s 50 day simple moving average is $36.52 and its 200-day simple moving average is $28.56. Azenta, Inc. has a one year low of $15.93 and a one year high of $50.06. The company has a market cap of $2.07 billion, a P/E ratio of -13.06 and a beta of 1.47.
Azenta (NASDAQ:AZTA – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.11 by $0.17. Azenta had a negative net margin of 26.86% and a positive return on equity of 1.41%. The business had revenue of $167.09 million during the quarter, compared to analysts’ expectations of $160.16 million. Analysts anticipate that Azenta, Inc. will post 0.69 EPS for the current fiscal year.
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
Read More
- Five stocks we like better than Azenta
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Azenta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta Inc and related companies with MarketBeat.com's FREE daily email newsletter.
